"Laboratory studies have shown that the nasal spray provides protection against both the original Wuhan strain and the Delta strain of Indian origin, as well as British, South African and Brazilian strains," the report said.
According to the scientific director of Icosagen, Marta Charter Jr., laboratory studies have so far confirmed that the developed nasal spray protects equally well against all strains of coronavirus that cause the greatest concern.
“Together with our team, we are constantly monitoring changes in the virus and proactively testing the ability of the BioBlock nasal spray to neutralize those strains that are not yet widespread,” said Marta Charter Jr.
The decision to produce and market BioBlock was made by the Department of Health based on the opinion of the Frontier Products Panel. It is noted that from a legal point of view, this is not a medicine or medical device, but the information on the product and information on the packaging has been agreed with both the Department of Medicines and the Department of Health.
According to the developers, BioBlock is an innovative Estonian product, the concept of which was developed by the Icosagen researchers under the guidance of Professor Marta Ustav. A consortium was formed to develop and market BioBlock. The technology of the product is patented.